To the Editor:
Central tenets of quality control (QC) and quality assurance are that (a) controls should be handled by the regular staff, and (b) they should be treated the same way as an equivalent patient specimen. This is not always adhered to in routine practice, and recent problems with blood collection tubes underline this point (1) (2) (3) (4) . Collection of blood in certain batches of Vacutainer ® SST tubes was associated with errors in some immunoassays on certain immunoassay platforms [e.g., biases of 20% to 30% for total thyroxine (T 4 ), total triiodothyronine (T 3 ), and cortisol and Ϫ15% to 20% for follicle-stimulating hormone (FSH)]. These errors have been attributed to contamination of samples with surfactants that are used to coat the tubes; the surfactant can release reagent antibodies from some solid-phase materials used in immunoassay methods (5, 6 ) .
Blood specimens for testing are removed through a metal needle into a blood collection tube. The tube and its contents are centrifuged to isolate serum, and the serum is either sampled directly from this tube or transferred to another tube from which a sample is removed for analysis. In contrast, a QC material is poured into a sample cup or tube from which it is sampled for analysis. Thus, the control material, unlike the blood specimen, does not come into contact with the surface of a metal needle or the contents of a blood collection tube.
We reasoned that adverse effects of additives in blood collection tubes would be apparent if control materials were poured into blood collection tubes and processed in the same way as blood. To test this, we analyzed control materials that were poured into our current batch of SST tubes or into SST tubes from the variant lot shown to be the source of an immunoassay interference. We did not introduce the control material through a needle because we, like other laboratories, strive to limit the use of needles. The tubes were then processed as if they were routine blood specimens, and the materials were analyzed.
We used 3 control materials: Performance Verifier 1 (lot no. L5782; Ortho Clinical Diagnostics), Lyphochek Immunoassay Plus Control (lot no. 40160), and Lyphochek Anemia Control (lot no. 43100; both from Bio-Rad Laboratories). We also For common chemistry tests (glucose, urea, creatinine, sodium, potassium, chloride, iron, carbon dioxide, amylase, lipase, calcium, magnesium, phosphate, cholesterol, triglycerides, uric acid, total protein, albumin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, creatine kinase, ␥-glutamyl transpeptidase, alkaline phosphatase, total bilirubin, conjugated bilirubin, and unconjugated bilirubin) performed on the Vitros 950AT (Ortho Clinical Diagnostics), we observed no differences between results for the control analyzed directly or after processing in the current or in the variant lot of SST tubes. Results for all replicates of the controls were within the established QC ranges for all analytes for all of the samples. This is in accord with the absence of any reported biases for common chemistry tests in tubes from affected batches.
By contrast, the endocrine tests run on an Immulite 2000 (Diagnostic Products Corporation) showed significant processing-dependent differences in the results for the analytes previously affected by surfactants in SST tubes (Table 1) . Total T 4 results for all of the controls processed in SST tubes from the variant lot were above the established QC intervals in all tubes (triplicate) and at all concentrations of the controls. Several of the total T 3 and cortisol results for the QC samples were at or above the established QC interval and would be regarded with suspicion (3 of 9 tubes for T 3 and 2 of 9 tubes for cortisol). The results for FSH had the reported negative bias, and a substantial number of QC results (5 of 9 tubes) were at or outside the limits of the established QC intervals. As expected, for the controls processed in the current lot of SST tubes and for controls that had not come into contact with an SST tube, control limits were not exceeded for the overwhelming majority of results (70 of 71 results, with 1 missing value).
Other factors, such as the volume of the control material, length of incubation (ϳ2 h) in the tube, and contact with the stopper and its lubricant, may influence the magnitude of tube effects. We filled tubes with only 1 mL of control material so as to produce high concentrations of additive and thus maximize any possible effects of the additives on the assays investigated in this study.
Our results emphasize the benefit of strict adherence to one of the basic tenets of QC, namely, that control specimens should be treated identically to specimens from patients. This strategy has revealed the interference attributable to the additives in the variant lot of SST tubes and, had it been in place, would have alerted the laboratory to the interference. We recommend that laboratories consider including this strategy in their QC plan. Periodic or routine processing of controls in blood collection tubes should provide a timely warning of possible interferences by additives in blood collection tubes.
Tissue Differences in the Expression of Mutations and Polymorphisms in the GRHPR Gene and Implications for Diagnosis of Primary Hyperoxaluria Type 2
To the Editor: Primary hyperoxaluria type 2 (PH2; OMIM 260000) is an inherited disease of endogenous oxalate overproduction arising from mutations in the GRHPR gene encoding glyoxylate reductase. The disease typically presents with urolithiasis or recurrent urinary tract infections and increased urinary oxalate (1 ) . The diagnosis may be supported by l-glyceraciduria, although this does not occur in all cases (2 ) . Definitive diagnosis is currently based on demonstration of diminished glyoxylate reductase activity in a liver biopsy (3 ), although DNA analysis offers a noninvasive method.
The GRHPR gene maps to the centromeric region of chromosome 9 (4 ) and, from Northern blot analysis (5 ), is ubiquitously expressed, although the bulk of enzyme activity is found in the liver (3, 5 ) . Among the described mutations and polymorphisms (5, 6 ) , c.103delG accounts for 37% of mutant alleles, allowing diagnosis of PH2 to be made by genetic testing (5 ) . One of the polymorphisms, c.579GϾA, occurs in exon 6, and the G allele has been shown to have a frequency of 0.68 in genomic DNA from PH2 patients (5 ) .
While evaluating leukocyte cDNA for identifying mutations and demonstrating potential splice defects in this gene, we found a lack of expression of mutations in leukocyte cDNA, in contrast to liver cDNA and genomic DNA from the same individual.
We studied liver and blood samples from a patient who presented clinically with features of PH and who subsequently was found, on liver enzyme analysis, to have PH2 (2 ) . Genomic DNA was prepared from EDTA-whole blood with the QIAamp DNA Blood Mini Kit (Qiagen). RNA was isolated from liver by homogenization in RNA isolator (Sigma Genosys) and from blood with the QIAamp Blood Mini Kit (Qiagen), according to the manufacturer's instructions. Reverse transcription-PCR was carried out using a Sensiscript ® Reverse Transcriptase Kit (Qiagen). Genomic DNA was amplified with intronic primers flanking exons 6 and 7, and cDNA was amplified with primers designed to amplify across intron-exon boundaries (5 ) . Sequencing of PCR products was performed on an ABI 3100 (Applied Biosystems) sequencer either directly after purification using the QIAquick PCR Purification Kit (Qiagen) or after cloning into TA-vector (Invitrogen).
Analysis of GRHPR genomic DNA showed a homozygous 2-bp deletion (c.608_609delCT) mutation and a G allele at position c.579 of cDNA (Fig.  1A) . The same genotype was observed in liver cDNA (Fig. 1B) . Leukocyte cDNA, however, showed a heterozygous pattern for the mutation as well as the c.579G/A polymorphism. After cloning, 2 transcripts were identified. One of these had the CT deletion mutation and c.579G (Fig. 1C) ; the other transcript had no mutation and contained the A allele at c.579 (Fig. 1D) . The discrepancy was verified by repeat analysis and by analysis of other family members. All controls, including reverse transcriptase-negative control and DNA-free PCR reactions, were negative.
The most likely explanation for these findings, which affect expression of mutations and a polymorphic site, is the presence of 2 highly homologous genes with different expression profiles. A BLAST search (http:// Clinical Chemistry 51, No. 12, 2005 
